Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment. - Wikidata - thesis-toulmin - TriplyDB

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

http://www.wikidata.org/entity/Q37639367

about

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs.Induction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovani Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct States of Infection of Humans with Leishmania infantum.Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation.Biomarkers for Zoonotic Visceral Leishmaniasis in Latin America

P2860

Q26866450-D062D8DE-B36E-4066-A10A-7E49AEF3842C Q33429539-AE0F8FF6-3C91-423F-988E-B25212468DBC Q35112512-3B4A849C-EBAF-4250-9100-8057A1962E96 Q35909887-1FC73E8C-1248-452D-AD7A-65C98349DE15 Q36187247-806EB453-D006-4C8B-B36B-C911908C7E94 Q41622831-F7E2ED2C-E093-44E8-95B0-35F78BC107B7 Q57952511-B8790026-63B2-488C-842B-16892F9D2EEE

P2860

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

http://www.wikidata.org/entity/Q37639367

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@en

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@nl

type

label

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@en

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@nl

prefLabel

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@en

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@nl

P1433

Q37639367-0258F604-8DA0-49E5-B6B2-5E905052EC2F

P1476

Q37639367-A68C4BE4-D901-46EF-99B7-36BA8398D48E

P2093

Q37639367-02F3A6B6-5191-4419-9535-729BF2C49CEB

Q37639367-1309CD9F-86B6-4A2E-88F7-CDD07AC47F17

Q37639367-1321177F-C9D8-4229-89A0-E6DBA9C524B8

Q37639367-1B954245-280E-4DCD-9B8D-C01C1457E562

Q37639367-41F140C6-B54C-4EE3-99E1-90C403E23848

Q37639367-92B02935-60A5-4BFE-B469-B72112BBE645

Q37639367-A6358A57-1C0B-45F1-89B7-3E492CEF08FA

Q37639367-B310D721-997D-49E5-AB06-068CB7A303F4

Q37639367-B353A5DB-B8F1-4036-B68B-7FC6E57B465F

Q37639367-D60ABD02-E1F6-4786-9053-076C4F16FE61

P2860

Q37639367-0962DA96-DC66-4635-AB2F-727D8458AADA

Q37639367-1388B7AF-28A7-453B-BE3B-274C50A76ED7

Q37639367-1ADE9FA9-C6C4-4799-8131-9746937DDEAA

Q37639367-1E0278B5-48E1-4570-8E53-D647599888E7

Q37639367-218FB996-3229-4A55-AE31-E87D6D2A5F30

Q37639367-26E5094E-304A-4976-8F94-968E7340666C

Q37639367-287DE488-EDC1-4B36-A070-0817107794B2

Q37639367-410E6E8D-65F3-4D00-A822-C16C72AFCFFF

Q37639367-4838203B-25FB-4556-9CD2-99E75B32C454

Q37639367-4D81DB01-2CAD-428B-B8E2-85FF50F90F34

P2888

Q37639367-FEBDEC37-25C3-4B61-90E7-CF13F3F27FC9

P304

Q37639367-65ECAF30-9FB1-4355-B80E-CCDF8B5F5FCE

P31

Q37639367-5C9D2E1D-650C-4298-8EF4-4BBA73C3175A

P356

Q37639367-B095702F-3B6D-4591-A0FC-9C4DA08EDEEB

P433

Q37639367-C88B9DE3-2DEF-4941-96F4-38930AC45A34

P478

Q37639367-9036E2FB-D6AF-4279-9543-CD54D4234DD7

P50

Q37639367-57DE2268-4721-4119-956B-7AD1B28C7729

P577

Q37639367-7764B8C5-180B-4C9C-AE6F-BE6AB0B628FB

P5875

Q37639367-6B9276DA-92D4-4184-BA79-110A5C5EF3DF

P698

Q37639367-FD604CFE-283D-4417-BABE-C9C59C034B7B

P921

Q37639367-5B847D01-6B2D-456E-9A92-0CD07FE37F7F

Q37639367-A07F8F3A-E92A-48CC-B37E-B8ED2D0C1991

P932

Q37639367-6F6FD5C7-A540-40B9-A4E6-64691FBD4CE0

P356

S10096-013-1999-1

P1433

European Journal of Clinical Microbiology & Infectious Diseases

P1476

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

@en

P2093

A Bhatia

http://www.w3.org/2001/XMLSchema#string

A Ribeiro de Jesus

http://www.w3.org/2001/XMLSchema#string

A Vallur

http://www.w3.org/2001/XMLSchema#string

D Mondal

http://www.w3.org/2001/XMLSchema#string

E Vieira de Melo

http://www.w3.org/2001/XMLSchema#string

J Guderian

http://www.w3.org/2001/XMLSchema#string

M Todt

http://www.w3.org/2001/XMLSchema#string

P Lima dos Santos

http://www.w3.org/2001/XMLSchema#string

R Almeida

http://www.w3.org/2001/XMLSchema#string

S G Reed

http://www.w3.org/2001/XMLSchema#string

P2860

Leishmaniasis worldwide and global estimates of its incidence

Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis

Potential role for interleukin-10 in the immunosuppression associated with kala azar

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis

Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients

More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects

Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.

P2888

s10096-013-1999-1

P304

639-649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10096-013-1999-1

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258204246

http://www.w3.org/2001/XMLSchema#string

P698

24173820

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

P932

3955411

http://www.w3.org/2001/XMLSchema#string